type2 diabetes
Conditions
Interventions
Group 1 taking single administration of DPP-4 inhibitor
Start with the basic dose determined by each clinic
Changing dose and administration should be determined by the doctor in charge
Treatment peri
Sponsors
QOL study group for oral anti-diabetic agent
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Newly treated with any oral anti-diabetic drugs and inadequate glycemic control(HbA1c 6.5-9.0%[the JDS]/6.9-9.4%6.9-9.4%[the NGSP] in spite of diet and exercise therapy for over 4 weeks 2)Age of 20<=, 80> 3)Out patients of either gender 4)Patients who agree to participate in the study, and who are able to start in 12 weeks
Exclusion criteria
Exclusion criteria: 1)type1 diabetes(CPR blood test and anti-GAD test is recommended) 2)Taking any anti-diabetic drugs 3)Severe ketosis, precoma, diabetic coma 4)Hepatic dysfunction(ALT <= 3times the upper limit of normal) 5)Gastrointestinal dysfunction as diarrhea or vomiting 6)Severe infection, severe injury. Before and after accepting surgery 7)Pregnant or suspected to be pregnant 8)History of hypersensitivity to any component of testing drugs 9)History of cancer or being treated for cancer 10)Whom the doctor in charge decided not to be appropriate for this study on the point of medical reason
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Scores in QOL questionnaire at 4th week | — |
Secondary
| Measure | Time frame |
|---|---|
| Scores in QOL questionnaire at 12th week Analyses of each item score in the questionnaire for each drug Analyses of intra-class correlation in the questionnaire for each drug The changing rate of HbA1c for each drug Completion rate for each drug treatment Patient adherence to each drug | — |
Countries
Japan
Outcome results
None listed